MBLX Metabolix, Inc. featured news, full reports, and detailed charts
Metabolix, Inc. (MBLX) Wrap Up:
We are a bioscience company that develops and plans to commercialize environmentally sustainable, economically attractive alternatives to petroleum-based plastics, chemicals and energy. Our strategy is to develop technology platforms that integrate advanced biotechnology with current industrial practice and to commercialize these platforms with industry leading strategic partners. Our first platform, which we are commercializing through Telles, a joint venture with Archer Daniels Midland Company, or ADM, is a proprietary, large-scale microbial fermentation system for producing a versatile family of polymers known as polyhydroxyalkanoates, which we have branded under the name Mirel™. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f13%2f0001047469-08-002672.html#FIS_BUSINESS"www.metabolix.com
98 Employees
Founded in 1992
Metabolix, Inc. (MBLX:NASDAQ)
LAST $10.45 USD
CHANGE TODAY +0.41 4.08%
VOLUME 118.1K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Metabolix, Inc. (MBLX)
|
OPEN
$10.03
|
PREVIOUS CLOSE
$10.04
|
|
|
DAY HIGH
$10.50
|
DAY LOW
$9.80
|
|
|
52 WEEK HIGH
10/16/09 - $13.45
|
52 WEEK LOW
03/12/09 - $4.62
|
|
|
MARKET CAP
272.2M
|
AVERAGE VOLUME 3 mo
320.5K
|
|
|
DILUTED EPS TTM
$-1.61
|
SHARES OUTSTANDING
26.0M
|
|
|
MBLX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Brazil's 'Organic' Plastics
06/24/2008 12:01 AM ET
I Have Just One Word for You: Bioplastics
06/19/2008 5:00 PM ET
The Greening Of Metabolix
05/07/2007 5:00 AM ET
Creative Destruction—for the Environment
04/02/2007 12:26 PM ET
related news
Investrend - 11/16/2009 1:49 AM ET
MBLX Top Compensated Officers
Mr. Richard P. Eno
Chief Executive Officer, President and Execut...
Age: 48
Total Annual Compensation: $237.5K
Mr. Joseph D. Hill
Chief Financial Officer, Principal Accounting...
Age: 46
Total Annual Compensation: $180.8K
Dr. Oliver P. Peoples Ph.D.
Chief Scientific Officer, Vice President of R...
Age: 50
Total Annual Compensation: $236.7K
Ms. Sarah P. Cecil
Secretary and General Counsel
Age: 57
Total Annual Compensation: $220.0K
Mr. Johan van Walsem
Vice President of Strategy and Commercial Dev...
Age: 46
Total Annual Compensation: $212.5K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Metabolix, Inc. (MBLX)
Metabolix Inc. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
10/29/2009
Metabolix Inc. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, total revenue was $611,000 against $351,000 a year ago. Loss from operations was $9,530,000 against $10,268,000 a year ago. Net loss was $9,417,000 or $0.14 per basic and diluted share against $9,728,000 or $0.42 per basic and diluted share a year ago. For the nine months, total revenue was $1,220,000 against $1,156,000 a year ago. Loss from operations was $28,904,000 against $29,550,000 a year ago. Net loss was $28,198,000 or $1.23 per basic and diluted share against $27,101.000 or $1.19 per basic and diluted share a year ago. Through the first nine months of 2009, net cash used in operating activities was $19.9 million, as compared to net cash used of $14.7 million for the comparable period of 2008. The increase in cash usage for the first nine months of 2009 is attributable to the increased operational needs of the business, as detailed above, and to decreased cash receipts in 2009 versus 2008. The decrease in cash receipts for the first nine months of 2009 is a result of the timing of pre-commercial cost sharing payments received from ADM, a decrease in funds received from investment income, a decrease in proceeds received from the exercise of stock options, and lower grant revenue from the Strategic Environmental Research Development Program grant that expired in February 2009. Purchase of property and equipment was $911,000 against $746,000 a year ago.
Metabolix, Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on October 29, 2009).
10/29/2009
Metabolix, Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on October 29, 2009).
Metabolix, Inc. Reports Net Cash Used in Operating Activities for the Third Quarter Ended September 30, 2009
10/29/2009
Metabolix, Inc. reported earnings results for the third quarter ended September 30, 2009. For the third quarter, net cash used in operating activities was $7.3 million which represents a planned increase in cash usage from $4.0 million used during the second quarter of 2009 and an increase over the $6.4 million used during the comparable period of 2008. This is consistent with the company intent to continue to invest in additional operational capabilities in connection with the planned production start up of the Clinton manufacturing facility.
MBLX Competitors
| Company | Last | Change |
| Cereplast Inc | $0.11 USD | 0.00 |
| ecoSolutions Intl | $0.05 USD | 0.00 |
| Kaneka Corporation | ¥571.00 JPY | -5.00 |
| PERF Go-Green Holdings Inc | $0.06 USD | 0.00 |
| Stanelco | 0.42 GBX | +0.03 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | MBLX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 148.6x |
|
| Price/Book | 7.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 124.8x |
|
|
MBLX |
||
|
MBLX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Metabolix, Inc.
More news for MBLX
Metabolix, Inc., Q3 2009 Earnings Call Transcript
Metabolix, Inc., (MBLX) Q3 2009 Earnings Call October 29, 2009 4:30 pm ET Executives [Laurie Shupe] - Investor Relations Richard P. Eno - President, Chief Executive Officer, Director Joseph D. Hill - Chief Financial Officer, Treasurer Oliver Peoples - Co-founder and Chief Scientific Officer Analysts Michael Cox - Piper Jaffray Laurence Alexander - Jefferies & Company, Inc. Jeff Osborne - Thomas Weisel Partners Pamela Bassett - Cantor Fitzgerald JinMing Liu - Ardour Capital Presentation Operator Good afternoon ladies and gentlemen my name is and I will be your conference operator today. At this time I would like to welcome everyone to the Metabolix Incorporated Third Quarter 2009 Earnings Conference Call. (Operator Instructions). At this time I would like to turn the conference over to Miss Laurie Shupe. Please go ahead. Laurie Shupe Thank you, and good afternoon everyone. Metabolix released third quarter 2009 financial results after the market closed today. If you do not have a copy one may be found on the website at www.metabolix.com, in the Investor Relations section. Making the presentation today will be Richard Eno, President and Chief Executive Officer of Metabolix and Joseph Hill Chief Financial Officer of the company; they are joined by Oliver Peoples, a co-founder of Metabolix and Chief Scientific Officer. Before we begin our formal remarks, I need to remind everyone that part of our discussion today will include forward-looking statements. These statements are not guarantees of ...Click here to read the whole Article (external link)
Metabolix Announces Commencement of Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Metabolix, Inc. (NASDAQ: MBLX - News), a bioscience company focused on developing sustainable solutions for plastics, chemicals and energy, today announced that it has commenced a public offering of shares of its common stock pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission (the "SEC"). Jefferies & Company and Thomas Weisel Partners LLC will serve as the underwriters for this offering. The underwriters also have the option to purchase up to an additional 15 percent of the offered amount of common stock from the Company at the public offering price, less underwriting discounts and commissions, within 30 days, to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds it receives from the offering for working capital and other general corporate purposes. The shares will be issued pursuant to an effective shelf registration statement that was previously filed with the SEC and was declared effective on January 30, 2008. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website ...Click here to read the whole Article (external link)
METABOLIX, INC. Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue611 348 261 399 Cost of Revenue - - - - Gross Profit611 348 261 399 Operating ExpensesResearch Development6,173 6,323 6,008 6,154 Selling General and Administrative3,968 3,938 3,714 3,587 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(9,530)(9,913)(9,461)(9,342)Income from Continuing OperationsTotal Other Income/Expenses Net - 241 352 438 Earnings Before Interest And Taxes(9,417)(9,672)(9,109)(8,904)Interest Expense - - - - Income Before Tax(9,417)(9,672)(9,109)(8,904)Income Tax Expense - - - - Minority Interest - - - - Net Income From Continuing Ops(9,417)(9,672)(9,109)(8,904)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - &nbs...Click here to read the whole Article (external link)
METABOLIX, INC. Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (All dollar amounts are stated in thousands) Forward Looking Statements This quarterly report on Form 10-Q contains "forward-looking statements" within the meaning of 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In particular, statements contained in the Form 10-Q, including but not limited to, statements regarding our future results of operations and financial position, business strategy and plan prospects, projected revenue or costs and objectives of management for future research, development or operations, are forward-looking statements. These statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as "may," "will," "should," "expects," "plans," "anticipate," "intends," "target," "projects," "contemplates," "believe," "estimates," "predicts," "potential," and "continue," or similar words. Although we believe that our expectations are based on reasonable assumptions within the limits of our knowledge of our business and operations, the forward-looking statements contained in this document are neither promises nor guarantees. Our business is subject to significant risk and uncertainties and there can be no assurance that our actual results will not differ materially from our expectations. These forward looking statements include, but are not limited to, statements concerning: future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development and commercialization, plans and objectives for present and future research and development and results of such research and development, p...Click here to read the whole Article (external link)
Metabolix downgraded by Ardour Capital
Quotes for MBLX - Yahoo! Finance #screen,#masthead{text-align:center;margin:0;width:752px;} #screen.xpand,#masthead.xpand{width:100%;} #screen.xpand #yfncsubtit{width:100%;} #masthead{padding-bottom:12px;} #leftcol,#rightcol{margin:0;} #leftcol{width:155px;float:left;} #rightcol{width:585px;} #content{width:752px;} #footer {clear:both;} /*/*/ body{text-align:center;} #screen{text-align:left;min-width:700px;width:62.5em;width:expression( document.all.footer ? (document.all.footer.offsetWidth>1000) ? '980'+'px' : document.all.footer.offsetWidth :'62.5'+'em') ;margin:auto;border:1px solid #FFF;} #screen.xpand{width:100%; text-align:center} #portfolio{margin:10px auto;} #hdrads{margin:10px auto 0 auto;} #masthead,#leftcol,#rightcol{margin:0;} #masthead{width:100%;} #leftcol{float:left;width:18%;} #rightcol{float:right;width:80%;} #content{width:100%;} #footer{clear:both;text-align:center;padding:10px 0;width:60em;margin:auto;border:0px solid #FFF;} #leftNavTable,#yfncmh,#yfncmkttme,#yfncduplgnwrn,#yfncpsnlbar,#yfnctitbar,#y fncsubtit,#yfncbrobtn,#yfncsumtab, .yfnc_systitlelinea1,.yfnc_systitlelineb1,.yfnc_modtitlew1{ width:100%;} #yfncmh{width:100%;} .yfncsumdatagrid{background:#DCDCDC;width:100%;} .yfnc_modtitlew2{width:49%;} /**/ .yfncnhl{color:#666;margin-bottom:10px;} .yfncnhl .yfncnhlbl{color:#000;width:1.6em;text-align:center;} .yfncnhl .yfncnhltt{color:#000;width:50px;padding-top:2px;} .yfncnhltt { position: relative; } .yfncnhltt a { position: relative; display: block; /* opera */ width: 42px; height: 31px; } .yfncnhltt img { border: 0; } .yfncnhltt img.video_play { position: absolute; bottom: 2px; left: 2px; width: 13px; height: 14px; } #yfiunv table td, #yfiadvdec table td { width: 1%; } #yfiunv table td.name, #yfiadvdec table th.first, #yfiadvdec table td.first { width: 10%; white-space: normal; } #leftcol{display:none;} #rightcol{display:block;} ...Click here to read the whole Article (external link)
MBLX prices stock offering
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...Click here to read the whole Article (external link)
Metabolix Prices Common Stock Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Metabolix, Inc. (NASDAQ: MBLX - News), a bioscience company focused on developing sustainable solutions for plastics, chemicals and energy, today announced that it has priced a public offering of 3.0 million newly issued shares of its common stock at a public offering price of $9.00 per share. The gross proceeds to Metabolix, before underwriting discounts and commissions and other offering expenses, from the sale of the shares are expected to be approximately $27 million. Jefferies & Company and Thomas Weisel Partners LLC are the underwriters for this offering. The Company has granted the underwriters a 30-day option to purchase up to 450,000 additional shares to cover over-allotments, if any. If the underwriters exercise their over-allotment option in full, gross proceeds from the offering, before underwriting discounts and commissions and other offering expenses, will be approximately $31 million. The offering is expected to close on November 16, 2009, subject to customary closing conditions. The Company intends to use the net proceeds it receives from the offering for working capital and other general corporate purposes. The shares will be issued pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (the "SEC") and was declared effective on January 30, 2008. The offering is being made by means of...Click here to read the whole Article (external link)
Metabolix Announces Completion of Common Stock Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Metabolix, Inc. (NASDAQ: MBLX - News), a bioscience company focused on developing sustainable solutions for plastics, chemicals and energy, today announced the completion of its previously announced underwritten public offering of 3,450,000 shares of its common stock at a price of $9.00 per share for gross proceeds of approximately $31 million. The aggregate number of shares sold reflects the exercise in full by the underwriters of their over-allotment option to purchase an additional 450,000 shares of common stock. The Company received net proceeds of approximately $29 million, after deducting underwriting discounts and commissions and estimated offering expenses. Jefferies & Company and Thomas Weisel Partners LLC served as the underwriters for this offering. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.The shares were issued pursuant to a shelf registration statement that was previously filed with the SEC and was declared effective on January 30, 2008. Copies of the final prospectus supplement and accompanying prospectus relating to these securities may be obtained from Jefferies & Company, Inc., 520 Madison Avenue, New York, NY 10022, 1-888-449-2342 or Thomas Weisel Partners LLC, One Montgomery Street, San Francisco, California 94104 (415) 364-2720.This press release shall not constitute an o...Click here to read the whole Article (external link)
METABOLIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial S
Show all filings for METABOLIX, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for METABOLIX, INC. 12-Nov-2009Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial S Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information prov...Click here to read the whole Article (external link)
Metabolix prices stock offering at $9 per share
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Would you like to leave a comment about Metabolix, Inc. MBLX
Find out what social network information about Metabolix, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Metabolix, Inc. there is more great information available at Realpennies.com